Financial Daily from THE HINDU group of publications
Friday, Sep 26, 2003
News
Features
Stocks
Port Info
Archives

Group Sites

 Corporate - Alliances & Joint Ventures


Glenmark, Canadian co tie-up for cardiac drug supply

Our Bureau

Mumbai , Sept. 25

GLENMARK Pharmaceuticals has tied up with Canadian-based Apotex for supply of a new generation bulk drug in cardiac segment in the US market.

The pharma firm has already started supplying developmental quantities to Apotex and supply of commercial scale quantities is expected next year, a company release said.

"The tie-up with Apotex is a significant development for the company's API business. Partnering with the largest Canadian generic firm is part of our strategic initiative to augment presence in the developed markets," Mr Glenn Saldanha, Managing Director and CEO, Glenmark Pharmaceuticals said.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Escorts puts off annual meet

Hind Sanitaryware shelves jt venture plans with German co
Siemens to supply gas turbines to Konaseema
KEC International gets new orders worth Rs 115 cr
Parryware to set up electronic flushing urinals in schools
Asahi India Glass clarifies
Shasun's pref allotment gets shareholders' nod
BILT to raise $75 m through GDR, FCCBs
On building lasting institutions
Marc Faber bullish on Asia — But bearish on US market
ICI to complete revamp exercise by end-fiscal
ONGC set to acquire HPCL stake in Mangalore Refinery
US agri major buys Prestige Foods' assets
Stand firm on ethics, values: J.J. Irani
Coimbatore Residency charts expansion plan
Chittivalasa jute mill impasse continues
Glenmark, Canadian co tie-up for cardiac drug supply
Companies told to keep pace with changing scenario
TRL promoters to submit final proposal soon
Casio India bets on digital cameras for big turnover
RINL posts Rs 521-cr profit

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |

Copyright © 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line